Phylloseptin-PBa—A Novel Broad-Spectrum Antimicrobial Peptide from the Skin Secretion of the Peruvian Purple-Sided Leaf Frog (Phyllomedusa Baltea) Which Exhibits Cancer Cell Cytotoxicity by Wan, Yuantai et al.
Phylloseptin-PBa—A Novel Broad-Spectrum Antimicrobial
Peptide from the Skin Secretion of the Peruvian Purple-Sided
Leaf Frog (Phyllomedusa Baltea) Which Exhibits Cancer Cell
Cytotoxicity
Wan, Y., Ma, C., Zhou, M., Xi, X., Li, L., Wu, D., ... Shaw, C. (2015). Phylloseptin-PBa—A Novel Broad-
Spectrum Antimicrobial Peptide from the Skin Secretion of the Peruvian Purple-Sided Leaf Frog (Phyllomedusa




Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license
(http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution and reproduction in any medium, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
Article
Phylloseptin-PBa—A Novel Broad-Spectrum
Antimicrobial Peptide from the Skin Secretion
of the Peruvian Purple-Sided Leaf Frog
(Phyllomedusa Baltea) Which Exhibits Cancer
Cell Cytotoxicity
Yuantai Wan 1,†, Chengbang Ma 1,†, Mei Zhou 1, Xinping Xi 1, Lei Li 1, Di Wu 1, Lei Wang 1,*,
Chen Lin 2,*, Juan Chavez Lopez 3, Tianbao Chen 1 and Chris Shaw 1
Received: 14 October 2015; Accepted: 23 November 2015; Published: 1 December 2015
Academic Editor: Stephen P. Mackessy
1 Natural Drug Discovery Group, School of Pharmacy, Queen’s University, Belfast BT9 7BL,
Northern Ireland, UK; ywan01@qub.ac.uk (Y.W.); c.ma@qub.ac.uk (C.M.); m.zhou@qub.ac.uk (M.Z.);
xxi01@qub.ac.uk (X.X.); lli12@qub.ac.uk (L.L.); dwu03@qub.ac.uk (D.W.); t.chen@qub.ac.uk (T.C.);
chris.shaw@qub.ac.uk (C.S.)
2 College of Basic Medical Science, Zhejiang Chinese Medial University, Hangzhou 310053, China
3 Perubiotech Eirl, Santiago de Surco, Lima 33, Peru; perubiotech@gmail.com
* Correspondence: l.wang@qub.ac.uk (L.W.); clin011@163.com (C.L.); Tel.: +44-28-9097-2200 (L.W.);
+86-571-8661-3609 (C.L.); Fax: +86-571-8661-3770 (C.L.)
† These authors contributed equally to this work.
Abstract: Antimicrobial peptides from amphibian skin secretion display remarkable
broad-spectrum antimicrobial activity and are thus promising for the discovery of new antibiotics.
In this study, we report a novel peptide belonging to the phylloseptin family of antimicrobial
peptides, from the skin secretion of the purple-sided leaf frog, Phyllomedusa baltea, which was
named Phylloseptin-PBa. Degenerate primers complementary to putative signal peptide sites of
frog skin peptide precursor-encoding cDNAs were designed to interrogate a skin secretion-derived
cDNA library from this frog. Subsequently, the peptide was isolated and identified using reverse
phase HPLC and MS/MS fragmentation. The synthetic replicate was demonstrated to have activity
against S. aureus, E. coli and C. albicans at concentrations of 8, 128 and 8 mg/L, respectively.
In addition, it exhibited anti-proliferative activity against the human cancer cell lines, H460,
PC3 and U251MG, but was less active against a normal human cell line (HMEC). Furthermore,
a haemolysis assay was performed to assess mammalian cell cytotoxicity of Phylloseptin-PBa.
This peptide contained a large proportion of α-helical domain, which may explain its antimicrobial
and anticancer activities.
Keywords: amphibian; antimicrobial; anticancer; peptides; molecular cloning; mass spectrometry
1. Introduction
The skins of frogs secrete a profusion of bioactive peptides, especially antimicrobial peptides,
which function in the killing of bacteria and their biofilms. In the 30 years since the discovery
of the first antimicrobial peptide (AMP) from this source, hundreds of such peptides have
been identified [1]. Phyllomedusinae is a sub-family of the Hylidae. It consists of 57 species
in seven genera: Agalychnis, Cruziohyla, Hylomantis, Pachymedusa, Phasmahyla, Phrynomedusa and
Phyllomedusa [2] which are widely distributed across Central and South America. The skin secretions
of phyllomedusine frogs have been found to produce a large number of AMPs with various
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antimicrobial activities. As a consequence of their structural similarities and secondary structural
characteristics, these AMPs have been classified into six families [3,4]. The peptides from different
families have distinctive primary structures. However, their biosynthetic precursors display strong
evolutionary homologies, particularly in their highly conserved signal peptide and N-terminal
pro-regions [5].
Phylloseptins are a family of AMPs recently discovered from the skin secretion of phyllomedusine
frogs. They were first isolated from the skin secretion of Phyllomedusa hypochondrialis and
Phyllomedusa oreades by Leite in 2005 [6]. As time passed, more phylloseptins were isolated and
identified from other species. The biosynthetic precursors of these phyllposeptins exhibited common
characteristic structures and shared highly-conversed domains within their precursor-encoding
cDNAs [7]. The primary structure of phylloseptins usually comprises 19–21 amino acid residues
and they are positively charged, C-terminally amidated, and additionally contain a α-helical domain.
The natural characteristic of amphiphilicity of these peptides was proposed to account for their
bioactivity via combination with cytoplasmic membranes, prior to their disruption. Since they display
little haemolytic activity, phylloseptins are regarded as preferentially targeting prokaryotic rather
than eukaryotic membranes [6,7].
In this study, a novel phylloseptin, named Phylloseptin-PBa, was isolated from the skin secretion
of Phyllomedusa baltea—the first report of phylloseptin peptides from this frog. The structure of the
peptide was obtained via “shotgun” cloning using 31RACE and 51RACE. The predicted primary
structure was confirmed by MS/MS fragmentation sequencing. The synthetic replicate of the peptide
was subjected to antimicrobial, anticancer and haemolysis assays in order to determinate its biological
function. Phylloseptin-PBa displayed inhibitory activity against E. coli, S. aureus and C. albicans.
Specifically, the growth of the standard Gram-positive bacterium, S. aureus, was significantly
inhibited by Phylloseptin-PBa, but the peptide also inhibited the pathogenic yeast, C. albicans,
at the same minimal inhibitory concentration (MIC). A further study was carried out to determine
the concentration of Phylloseptin-PBa at which no growth of S. aureus and C. albicans occurred and
this was found to be 8 mg/L in both cases. However, Phylloseptin-PBa was not active against
E. coli at concentrations up to 128 mg/L. It also possessed a relatively low potency of haemolysis at
concentrations that were effective against S. aureus and C. albicans. Meanwhile, the anticancer activity
assay of this peptide indicated that it was active on all three human cancer cell lines tested (H460, PC3
and U251MG) but was less active on a normal human microvessel endothelial cell line (HMEC-1).
2. Results
2.1. Shotgun Cloning of Novel Peptide Precursor-Encoding cDNA
Using a Phyllomedusinae-specific degenerate primer, designed to the highly conserved signal
region from previously sequenced peptides from phyllomedusine frogs, a full-length cDNA encoding
Phylloseptin-PBa was successfully and repeatedly cloned (at least 25 clones were represented) from
the skin secretion-derived cDNA library of Phyllomedusa baltea. Through bioinformatic searches, the
putative mature peptide was analysed using the NCBI BLASTp program, which demonstrated that
Phylloseptin-PBa was a new member of the phylloseptin family. The nucleotide and translated
open reading frame amino acid sequences of precursor-encoding cDNA are shown in Figure 1.
Essentially, there were several defining characteristics of note: (1) the open reading frame of the
precursor consisted of 66 amino acid residues, which containing the mature peptide of 19 amino acids;
(2) A highly- conserved putative signal peptide region of 21 amino acid residues; (3) An acidic
amino acid residue-rich “spacer” peptide containing 22 residues; (4) A classical propeptide convertase
processing site (-KR-); (5) A mature active peptide encoding domain that contained 19 amino
acid residues with a typical phylloseptin N-terminal; (6) A C-terminal G residue that acts as an
amide donor for the L residue that terminates the mature peptide. According to the results of
BLAST analyses, Phylloseptin-PBa showed a high level of structural homology to phylloseptins
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from other frogs of the sub-family, Phyllomedusinae, including PS-7 to PS-11 from Phyllomedusa
hypochondrialis, PS-7, 8, 12 and 15 from Phyllomedusa azurea, PS-1 from Phyllomedusa sauvagei and PS-B
from Phyllomedusa bicolor [3]. The alignment of amino acid sequences of the precursor isolated from
Phyllomedusa baltea with the top hits found in the database, are shown in Figure 2. The nucleotide
sequence of the Phylloseptin-PBa precursor has been deposited in the European Molecular Biology
Laboratory (EMBL) Nucleotide Sequence Database under the accession code LN810553.
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TATGGTTTCT ATCGTCCACC TTATCGAAGT GAACAATTTT TGAATCCAAT 
 
201ATACAATGTA ACATTTCATA ACTCTAAGGA GCACAATTAT CAATAATTGT 
TATGTTACAT TGTAAAGTAT TGAGATTCCT CGTGTTAATA GTTATTAACA 
251TCCCAAAATA CATTAAAGCA TATTTAACCA AAAAAAAAAA AAAAAAAAAA 
AGGGTTTTAT GTAATTTCGT ATAAATTGGT TTTTTTTTTT TTTTTTTTTT  
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LN810553   (1) MAFLKKSLFLVLFFGLVSLSICEEEKRETEEEENNQEEDDK---SEEKRFFSMIPKIAGGIASLVKNLG
AFR78285   (1) MAFLKKSLFFVLFLGLVSLSIRGEKKRETEEKEYDQGEDDK---SEEKRFLSLIPHIVSGVASIAKHFG
  P84567   (1) MAFLKKSLFLVLFLGLATLSICEEEKRETEEEEYNQEEDDK---SEEKRFLSLIPHAINAVSTLVHHFG
CAI26288   (1) MAFLKKSLFLILFLGLVPLSFCENDKREGENEE--EQDDDQ---SEEKRALGTLLKGVGSGKMVADQFG
AAO62959   (1) MAFLKKSLFLVLFLGLVSLSICEEEKRETEEKEYDQGEDDK---SEEKRFLSLIPHIVSGVAALAKHLG
ACG50814   (1) MAFLKKSLFLVLFLGFVSVSICEEEKRQEDEDEHVEEGENQEEGSEEKRGLLSVLGSVAKVPVIAEHLG
CAI77674   (1) MHFLKKSIFLVLFLGLVSLSICEKEKREDQNEEEVDENE---EASEEKRGLMSILGKVAGFKPKENVQK
  B5LUQ9   (1) MASLKKSFFLVLFLGLVSLSMCEEKKRENEDDAEDGNHE---EESEEKRGLVDFAKHVIGIASKLG---
  Q0VZ41   (1) MAFLKKSLFLVLFLGLVSLSICEEEKRETEEEEYNQEDDDK---SEEKRFLSLIPTAINAVSALAKHFG














Figure 1. Nucleotide and translated open-reading frame amino acid sequences of cloned cDNA
encoding the biosynthetic precursor of Phylloseptin-PBa. Double underlining indicates the putative
signal peptide sequence, single underlining indicates the mature peptide sequence and an asterisk
indicates the stop codon.
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Figure 2. Multiple alignment of the cloned cDNA-deduced amino acid sequence of Phylloseptin-PBa
obtaine in this study, with those of the top hits following NCBI-BLASTp analysis. Gaps have been
included to axi ize align ents. Black shading indicates identical a ino acid residues a ong all
the sequences, blue shading indicates consensus a ino acid residues, and green shading indicates
si ilar a ino acid residues.
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peptide was  obtained,  it was  subjected  to  full ms  scan  and  tandem mass  spectrometry  peptide 
Figure 3. Region of reverse phase HPLC chromatogram of Phyllomedusa baltea skin secretion showing
the absorbance peak (arrow) corresponding to Phylloseptin-PBa. The Y-axis shows the relative
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peptide was  obtained,  it was  subjected  to  full ms  scan  and  tandem mass  spectrometry  peptide 
Figure 4. Predicted singly- and doubly-charged y-ions and b-ions arising from MS/MS fragmentation
of Phylloseptin-PBa. Actual fragment ions observed following MS/MS fragmentation are indicated
in blue and red.
2.3. Peptide Synthesis
The solid-phase Fmoc peptide synthesis of Phylloseptin-PBa was found to be straightforward
and deemed to be highly successful. The observed molecular weight of Phylloseptin-PBa was
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2004.66 Da (Figure 5). Purification of the crude product was achieved by reverse phase HPLC.
Once the purified peptide was obtained, it was subjected to full ms scan and tandem mass
spectrometry peptide fragmentation (MS/MS fragmentation), in order to confirm its primary
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Figure 5. The MS full scan of synthetic phylloseptin‐PBa obtained from the LCQ Fleet electrospray 




the  I‐TASSER server, revealed  that  it contained a  large proportion of α‐helical domain  (Figure 6).  
The  side  chains  of  the  amino  acids  of  the  peptide  partitioned  into  two  planes,  indicating  their 
amphipathic nature. One side consisted of hydrophobic  residue side chains within  the helix axis, 




Figure  6.  Predicted  secondary  structure  of  Phylloseptin‐PBa  using  the  on‐line  protein  secondary 
structure prediction tool, I‐TASSER. 
Figure 5. The MS full scan of synthetic phylloseptin-PBa obtained from the LCQ Fleet electrospray
ion-trap mass spectrometer. The ions of m/z 669.33 and 1003.33 were triply charged and doubly
charged, respectively.
2.4. Secondary Structure Prediction of the Peptide
The predicted secondary structure of Phylloseptin-PBa, obtained through software modeling on
the I-TASSER server, revealed that it contained a large proportion of α-helical domain (Figure 6).
The side chains of the amino acids of the peptide partitioned into two planes, indicating their
amphipathic nature. One side consisted of hydrophobic residue side chains within the helix axis,
while the hydrophilic residue side chains were located on the opposite side. A helical wheel projection
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were  assessed.  Their  effects  on  the  Gram‐positive  bacterium,  Staphylococcus  aureus,  the  
Gram‐negative  bacterium,  Escherichia  coli,  and  the  yeast, Candida  albicans,  are  shown  in  Table  1. 
Phylloseptin‐PBa exhibited potent antimicrobial activity against Staphylococcus aureus and Candida 
albicans. More specifically, Phylloseptin‐PBa possessed the same MIC values of 8 mg/L against both 
organisms,  these  values  being  identical  to  their  MBCs  (Table  1).  Meanwhile,  Phylloseptin‐PBa 
showed much weaker antimicrobial activity against Escherichia coli with an MIC value of 128 mg/L. 
However,  Phylloseptin‐PBa  was  associated  with  a  relatively  low  cytotoxicity  (1.4%)  on  horse 
erythrocytes  at  a  concentration  of  8  mg/L,  but  this  rose  to  around  80%  at  a  concentration  of  
128 mg/L (Figure 8). 
Table 1. Minimal  inhibitory  concentrations  (MIC) and minimal bactericidal  concentrations  (MBC) 
values  of  Phylloseptin‐PBa  against  the  Gram‐positive  bacterium,  Staphylococcus  aureus,  the  
Gram‐negative bacterium, Escherichia coli, and the yeast, Candida albicans. 
Peptide name  MIC (mg/L) MBC (mg/L) 
S.Aureus  E.Coli  C.Albicans  S.Aureus  E.coli  C.Albicans 
Phylloseptin‐PBa  8  128  8  8  >512  8 
Figure 7. Helical wheel plot of Phyllos ptin-PBa. An amphipathic character was observed with side
chains of the hydrophobic residues (M4, L15, I8, F1, L19 I12, I5, V16, A9) partitioning to one side of
the molecule and the cationic amino acid groups (α-amino of G10, side-chain groups of amino acids
K7 and K17) appearing on the opposite side.
2.5. Antimicrobial and Haemolytic Activity of Phylloseptin-PBa
MICs, minimal bactericidal concentrations (MBCs) and haemolytic effects of Phylloseptin-PBa
were assessed. Their effects on the Gram-positive bacterium, Staphylococcus aureus, the Gram-negative
bacterium, Escherichia coli, and the yeast, Candida albicans, are shown in Table 1. Phylloseptin-PBa
exhibited potent antimicrobial activity against Staphylococcus aureus and Cand da albicans. More
specifically, Phylloseptin-PBa possessed the same MIC values of 8 mg/L against both organisms,
these values being identical to their MBCs (Table 1). Meanwhile, Phylloseptin-PBa showed much
weaker antimicrobi l acti ity again t Escherichia coli with an MIC value of 128 mg/L. However,
Phylloseptin-PBa was associated with a relatively low cytotoxicity (1.4%) on horse erythrocytes at
a concentration of 8 mg/L, but this ros to around 80% at a concentration of 128 mg/L (Figure 8).
Table 1. Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations
(MBC) values of Phylloseptin-PBa against the Gram-positive bacterium, Staphylococcus aureus,
the Gram-negative bacterium, Escherichia coli, and the yeast, Candida albicans.
Peptide Name MIC (mg/L) MBC (mg/L)
S. aureus E. coli C. albicans S. aureus E. coli C. albicans




Figure  8.  Haemolytic  activity  of  Phylloseptin‐PBa.  Percentage  of  haemolysis  was  calculated  in 
comparison to the positive control using TritonX‐100. 
2.6. Anti‐Proliferative Effects of Phylloseptin‐PBa on Human Cancer Cells 
Eleven  human  cancer  cell  lines  were  used  to  examine  the  anti‐proliferative  effects  of 
Phylloseptin‐PBa and they showed obvious activity in three of these: the lung cancer cell line (H460), 
the  prostate  cancer  cell  line  (PC3)  and  the  neurospongioma  cell  line  (U251MG),  respectively.  
The human microvessel endothelial cell line (HMEC‐1) was used to evaluate inherent cytotoxicity of 
Phylloseptin‐PBa  against  normal  human  cells.  It  showed  selective  cytotoxicity  against  the  three 
different cancer cell lines and lower cytotoxicity against HMEC‐1 cells (Figure 9). The IC50 values after 
a 24 h incubation, were 4.3 μM, 2.9 μM, 1.8 μM and 36.6 μM, respectively. 


































Figure 8. Haemolytic activity of Phylloseptin-PBa. Percentage of haemolysis was calculated in
comparison to the positive control using TritonX-100.
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2.6. Anti-Proliferative Effects of Phylloseptin-PBa on Human Cancer Cells
Eleven human cancer cell lines were used to examine the anti-proliferative effects of
Phylloseptin-PBa and they showed obvious activity in three of these: the lung cancer cell line
(H460), the prostate cancer cell line (PC3) and the neurospongioma cell line (U251MG), respectively.
The human microvessel endothelial cell line (HMEC-1) was used to evaluate inherent cytotoxicity
of Phylloseptin-PBa against normal human cells. It showed selective cytotoxicity against the three
different cancer cell lines and lower cytotoxicity against HMEC-1 cells (Figure 9). The IC50 values
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Specimens  of  Phyllomedusa  baltea  were  collected  in  Peru  by  PeruBiotech  E.I.R.L.  The  skin 
secretion (40 mg lyophilised dry weight) of captured adults was subsequently harvested using mild 
electrical  stimulation  of  the  dorsal  skin  surface.  Briefly,  the moistened  skin was  stimulated  by 
platinum electrodes (6 V DC; 4 ms pulse‐width; 50 Hz) for two periods of 20 s duration. After this, 
stimulated secretion was collected by washing from the frog skin using distilled, deionised water. 
These  skin secretions were  snap‐frozen  in  liquid nitrogen,  lyophilised and  stored at  −20  °C prior  
to analysis. 
3.2. Shotgun Cloning of Phylloseptin‐PBa Precursor‐Encoding cDNA 
Five  mg  of  lyophilised  Phyllomedusa  baltea  skin  secretion  were  dissolved  in  1  mL  of  cell 
lysis/mRNA  stabilisation buffer  (Dynal, Merseyside, UK). Magnetic oligo‐dT beads were used  to 
isolate  polyadenylated  mRNA  in  accordance  with  the  manufacturer’s  description  (Dynal, 
Merseyside, UK) and the isolated mRNA was subsequently subjected to RACE procedures to acquire 
full‐length prepropeptide nucleic acid sequence data by using a SMART‐RACE kit (Clontech, Oxford, 
UK)  essentially  as  outlined  by  the  manufacturer.  Briefly,  the  3′‐RACE  reactions  employed  a  
UPM  primer  (supplied  with  the  kit)  and  degenerate  sense  primer  
(5′‐ACTTTCYGAWTTRYAAGMSCARABATG‐3′) that were designed to highly‐conserved segments 
of the signal peptides of cDNAs cloned previously from other Phyllomedusa frogs within our group [7]. 
Figure 9. Dose-response curves of Phylloseptin-PBa on human cancer cell lines after a 24 h incubation.
Panels A, B, C and D show the peptide effects on H460 (lung cancer), PC3 (prostate cancer), U251MG
(neurospongioma), and HMEC-1 (microvessel endothelial cells). IC50 values were 4.3 µM, 2.9 µM,
1.8 µM and 36.6 µM, respectively.
3. Experimental Section
3.1. Specimen Acquisition
Specimens of Phyllomedusa baltea were collected in Peru by PeruBiotech E.I.R.L. The skin
secretion (40 mg lyophilised dry weight) of captured adults was subsequently harvested using mild
electrical stimulation of the dorsal kin surface. Briefly, the moistened skin was stimulated by
platinum electrodes (6 V DC; 4 ms pulse-width; 50 Hz) for two periods of 20 s duration. After this,
stimulated secretion was collected by washing from the frog skin using distilled, deionised water.
These skin secretions were snap-frozen in liquid nitrogen, lyophilised and stored at ´20 ˝C prior
to analysis.
3.2. Shotgun Cloning of Phylloseptin-PBa Precursor-E coding cDNA
Five mg of lyophilised Phyllomedusa baltea skin secretion were dissolved in 1 mL of cell
lysis/mRNA stabilisation buffer (Dynal, Merseyside, UK). Magnetic oligo-dT beads were used
to isolate polyadenylated mRNA in accordance with the manufacturer’s description (Dynal,
Merseyside, UK) and the isolated mRNA was subsequently subjected to RACE procedures
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to acquire full-length prepropeptide nucleic acid sequence data by using a SMART-RACE kit
(Clontech, Oxford, UK) essentially as outlined by the manufacturer. Briefly, the 31-RACE
reactions employed a UPM primer (supplied with the kit) and degenerate sense primer
(51-ACTTTCYGAWTTRYAAGMSCARABATG-31) that were designed to highly-conserved segments
of the signal peptides of cDNAs cloned previously from other Phyllomedusa frogs within our group [7].
The PCR cycling procedure was as follows: step one: initial denaturation: 90 s at 94 ˝C; 35 cycles:
denaturation 30 s at 94 ˝C; step two: primer annealing for 30 s at 58 ˝C; step three; extension
for 180 s at 72 ˝C. PCR products were gel-purified and cloned using a pGEM-T vector system
(Promega Corporation, Southampton, UK) and sequenced using an ABI 3100 automated sequencer
(Applied Biosystems, Foster City, CA, USA).
3.3. Identification and Structural Analysis of Phylloseptin-PBa
Five mg of lyophilised skin secretion from Phyllomedusa baltea, were dissolved in 0.5 mL
of TFA/water and cleared of microparticulates by centrifugation (2500ˆ g for 5 min).
The clear supernatants were pumped onto an analytical reverse phase HPLC Jupiter C5
column (250 mm ˆ 4.6 mm, Phenomenex, UK). Peptides were eluted from the HPLC column
with a linear gradient formed from 0.05/99.95 (v/v) TFA/water to 0.05/19.95/80.00 (v/v/v)
TFA/water/acetonitrile over 240 min at a flow rate of 1 mL/min. A Cecil CE4200 Adept gradient
reverse phase HPLC (Cecil, Cambridge, UK) was used and automatic collection of fractions was
performed at 1 min intervals. The calculated molecular masses of predicted novel mature peptides
from open-reading frames of cloned cDNAs were used to interrogate a mass spectral library of
skin secretion peptides from reverse phase HPLC fractions using MALDI-TOF mass spectrometry
(Perseptive Biosystems, MA, USA) in positive detection mode. The fraction containing a peptide
with a molecular mass identical to that of the deduced novel cDNA-encoded peptide was analysed
by MS/MS fragmentation sequencing using an LCQ-Fleet electrospray ion-trap mass spectrometer
(Thermo Fisher Scientific, San Francisco, CA, USA).
3.4. Solid-Phase Peptide Synthesis of Phylloseptin-PBa
Following confirmation of the unequivocal primary structure of this novel peptide, it was
chemically-synthesised by solid phase Fmoc chemistry using a PS4 automated solid-phase
synthesiser (Protein Technologies, Inc., Tucson, AZ, USA). All of the dry amino acids were weighed
and mixed with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
activator and added to the reaction vessel on the PS4 machine. Deprotection of the Fmoc groups
from the amino acids was performed in 20% piperidine in dimethylformamide (DMF). The coupling
of peptide bonds was performed in 1 M N-Methylmorpholine (NMM) in DMF. After the reaction
was complete, the peptide-resin mixture was washed by 30 mL of degassed dichloromethane (DCM)
and subsequently dried in a vacuum desiccator overnight. Peptide was cleaved from the resin using
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water. The confirmation of
structure of the synthetic peptide was accomplished using both reverse-phase HPLC and electrospray
mass spectrometry. This also established its degree of purity.
3.5. Antimicrobial Assays
Antimicrobial activity of the synthetic peptide was evaluated by means of determining MICs
using standard strains of Gram-negative bacteria, Gram-positive bacteria and pathogenic yeast.
The peptide was prepared in a concentration range of 1–512 mg/L and organisms were grown
in Mueller-Hinton broth (MHB) for 18 h. Peptide solutions were then mixed with microorganism
cultures (105 colony forming units (CFU)/mL) and placed into 96-well microtitre cell culture plates.
Plates were incubated for 18 h at 37 ˝C in an orbital incubator. Subsequently, the growth of
bacteria/yeast was assessed by determination of optical density (OD) at λ550 nm. The MIC values
were obtained according to the lowest concentrations of peptide at which no growth was detectable.
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Subsequently, 10 µL of each clear solution was inoculated onto Mueller Hinton agar (MHA) plates.
After 24 h, the minimum bactericidal concentrations (MBCs) were obtained, based on the definition
of MBC as the concentration of peptide in which colonies grew.
3.6. Haemolysis Assays
A 4% (v/v) suspension of red blood cells was prepared from defibrinated horse blood
(TCS Biosciences Ltd, Buckingham, UK) by repeated washings and centrifugations in sodium
phosphate-buffered saline (PBS). Peptide solutions of different concentrations were prepared
according to the description in the antimicrobial assay in a previous section. Horse red blood cell
suspension samples (200 µL) were incubated with a range of peptide concentrations, similar to the
antimicrobial activity assays, at 37 ˝C for 60 min and 120 min. Lysis of red cells was detected by
measurement of supernatants using an ELISA plate reader (Biolise BioTek EL808, Winooski, VT, USA)
with optical density set at λ550 nm. Positive controls consisted of a 2% (v/v) red cell suspension and
an equal volume of PBS containing 2% (v/v) of the non-ionic detergent, Triton X-100 (Sigma Aldrich,
St. Louis, MO, USA). Negative controls employed consisted of a 2% (v/v) red cell suspension and
PBS in equal volumes. The percentage of haemolysis was computed by the following formula:
% Haemolysis “ pA ´ A0q { pAx ´ A0qˆ 100% (1)
where A is the OD (λ570) for the mixture of peptide and suspensions, Ax is OD (λ570) for the positive
control and A0 is OD (λ570) for the negative control.
3.7. Cells Lines and Cell Culture
The human breast cancer cell lines (MB231, MB435s, MCF-7), the human prostate cancer cell
lines (DU145, PC3, LNCap), the human lung cancer cell lines (H838, H460 and H157), and the human
neuropongioma cell line (U251MG), were separately cultured employing RPMI-1640 culture medium
(Invitrogen, Paisley, UK), or Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, St. Louis, MO,
USA), with 1% penicillin streptomycin solution (Sigma) and 10% fetal bovine serum (FBS) (Sigma)
added. The human microvessel endothelial cell (HMEC-1) was employed to evaluate the cytotoxicity
of the peptide against normal human cells, and these cells were grown in 10% FBS, 10 ng/mL EGF,
10 mM L-Glutamine, 1% penicillin streptomycin supplemented MCDB131 medium (Gibco, Paisley,
UK). The selected cells were inoculated into 90 mm culture dishes (Nunc, Roskilde, Denmark) or into
75 cm2 culture flasks (Nunc). Following this, flasks were placed in an incubator with a humidified
environment containing 5% CO2.
3.8. Assessment of Cancer Cell Antiproliferative Activity Using the MTT Cell Viability Assay
Cancer cell line proliferation and viability were assessed using the MTT cell viability assay [8].
Briefly, each of the cancer cell lines was seeded at a density of 5ˆ 103 cells per well onto 96 well plates.
Following this, cell lines were prepared with gradient concentrations of peptide and incubated over
24 h. After this, 10 µL of 5 mg/mL yellow coloured MTT solution (Sigma) were added to all wells and
incubated again for 4 h. Once the supernatants were removed by a syringe, 100 µL of DMSO were
added to all wells after gently agitating in order to completely mix the formazan crystals that had
developed. A Synergy HT plate reader (BioTek, Winooski, VT, USA) was set at 550 nm for recording
the absorbance, and the statistical analysis of results was performed using Student’s t-test through
GraphPad Prism 5.0 software. The final results were considered to be statistically significant if the
p value was <0.05.
4. Discussion
Phylloseptins, a new family of antimicrobial peptides, has been recently described as
having primary structures containing 19–21 amino acid residues. Family members share
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similar structural attributes including their N-terminal regions and C-terminal amidation [6].
Phylloseptin-PBa reported here, was found to be structurally related to earlier reported
phylloseptins. The first domain of the precursor protein encoded a 22 amino acid residue
signal peptide and this displays around 90% similarity across the family [6,9]. These signal
peptides were characterized by the conservation of most residues in the N-terminal sequence:
Met-Ala-Phe-Leu-Lys-Lys-Ser-Leu-Phe-Leu-Val-Leu-Phe-Phe/Leu-Gly-Leu-Val-Ser-Leu-Ser-IIe-Cys-.
The following 24 amino acids encode an acidic amino acid residue-rich spacer domain which,
although its function has not been fully explained, may have a role to play in peptide storage or
packaging within secretory cells [5]. The third domain contained another highly conserved classical
-Lys-Arg-(-K-R-) propeptide convertase cleavage site. The fourth domain encoded the mature
peptide and consisted of 19 amino acids. It would appear that the length of these peptides plays an
important role in their actions. Like other phylloseptins, Phylloseptin-PBa also displayed a proline at
position 6 that affected the linearity of the structure [9]. The C-terminal residue of Phylloseptin-PBa
was the glycyl residue amide donor for this post-translational modification, which is quite a
common modification in many antimicrobial peptides. This amidation is thought to enhance the
net positive charge increasing the cationicity of the peptide, which would lead to enhancement of
the antimicrobial effect [8]. Based on the clearly identified structure of Phylloseptin-PBa, whose
structure was initially deduced from cloned skin cDNA of the frog, Phyllomedusa baltea, there was
clear structural similarity to homologues from Phyllomedusa sauvagei, Phyllomedusa hypochondrialis,
Phyllomedusa azurea and Phyllomedusa bicolor [4]. Many frogs produce antimicrobial peptides that have
overlapping structural features. Despite the fact that Phylloseptin-PBa was very similar in primary
structure to other members of the phylloseptin family with the same number of amino acid residues
and positive charge, secondary structure prediction analysis found that Phylloseptin-PBa had a
higher helical content and hydrophobicity [8]. Several researchers have reported that hydrophobicity
can enhance the interaction between peptides and bacterial membranes. On the other hand, it could
also result in increasing mammalian cell cytotoxicity [10].
The result of the antimicrobial assays revealed that Phylloseptin-PBa produced growth inhibition
on all three typical microorganisms tested. It had more potent antimicrobial activity on the yeast
and Gram-positive bacterium, but only had weak effects on the Gram-negative bacterium. More
specifically, the results showed that Phylloseptin-PBa possessed the same MIC value for C. albicans
and S. aureus. However, the MIC value of Phylloseptin-PBa on E. coli showed a low potency against
this organism. The higher potency of Phylloseptin-PBa against S. aureus, when compared with E. coli,
could be explained by the fact that cells of the former possess a single bilayer lipid membrane
(BLM), while Gram-negative bacteria have a rich acidic membrane that reduces the charge on their
surfaces [11,12]. This was an important observation in that Phylloseptin-PBa might be of use in
disseminated Gram-positive bacterial infections. Haemolytic activity of AMPs is an undesirable
side-effect as reported by Zhang et al [13]. According to structure/activity relationships, one of
the important features of AMPs is the proportion of their hydrophobic amino acid residues, which
normally constitute at least 50% of their entire amino acid sequences [14–16]. Hydrophobicity not
only increases the potency of antimicrobial peptides, killing bacteria via membrane disruption,
but also enhances the possibility of interaction with mammalian zwitterion membranes, which are
less negatively charged than bacterial membranes and have a higher content of cholesterol [14–16].
Similar to many other antimicrobial peptides, Phylloseptin-PBa contained over 50% of hydrophobic
amino acid residues, which resulted in a relatively high haemolytic effect at high concentrations but
was very low at MICs for S. aureus and C. albicans.
A growing number of researchers have shown that some antimicrobial peptides possess both
antimicrobial and anticancer activity, although the anticancer mechanism of these peptides is not
clearly known as yet. However, previous studies have indicated that antimicrobial peptides
kill cancer cells by cellular membrane lysis [17]. There are many structural similarities among
these peptides, mostly with regard to their cationicity and amphipathic nature. These common
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features have illustrated that membrane interaction is crucial for the disrupting effect of these
peptides, via rapidly binding with the plasma membrane of cancer cells producing cell death.
Therefore, the conclusions of these researchers have supported the “carpet” and “barrel-stave”
mechanisms for membrane lysis [14]. This may provide another option to traditional anticancer
chemotherapies, without strong side effects and low possible development of multi-drug resistance,
making antimicrobial peptides excellent candidates for novel anticancer therapy [18].
Anti-proliferative activity of Phylloseptin-PBa was examined by use of MTT cell viability assays
using eleven human cancer cell lines. Data showed that Phylloseptin-PBa had a broad-spectrum
of anticancer activity with but with selectivity in inhibiting different categories of cancer cell lines.
Compared to other cell lines, this peptide was more potent in inhibiting the growth of H460, PC3 and
U251MG cells. In addition, this peptide also possessed anti-proliferative activity for HMEC-1 cells at
the highest concentration of 0.1 mM in the MTT assay. This sensitivity bias of different cell lines with
the same peptide may be due to the different structures and components of cell membranes. Many
studies have found that cancer cells can over express O-glycosylated mucins and high molecular
mass glycoproteins on the cell membrane, which can provide additional negative charges [17–19].
However, in common with the antimicrobial mechanisms of AMPs, their anticancer mechanisms
are still unclear. Why the innate immune system produces peptides with multiple functions is also
still unknown. Nevertheless, with further studies in this area, more details of AMP action will be
discovered in order to elucidate their mechanisms. More significantly, cationic antimicrobial peptides
have outstanding advantages over conventional drugs which include their broad-spectrum activity,
rapid killing of cancer cells and obviation of conventional chemotherapy resistance. These factors
herald the possibility that AMPs may become a new option of treatment for cancer patients.
Recently, it has been discovered that phylloseptin peptides not only possess broad-spectrum
antibacterial and antifungal activities but also have the ability to release insulin to improve glucose
tolerance in mice. More specifically, this has been achieved using a synthetic replicate of the
peptide, phylloseptin-L2, on stimulating basal insulin secretion rates in BRIN-BD11 cells. Thus,
as there is a potential for developing these peptides into agents for treating Type 2 diabetes, there
is understandable interest in isolation and characterization of members of this peptide family [6,20].
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